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This commentary is aimed at summarizing the second plenary
session presented at the ISPOR 4th Asia-Pacific Conference held in
2010 and compare the issues on drug listing of Thailand, China,
and Australia. These countries have substantially different demo-
graphic and economic characteristics and health-care financing
structures and are in different phases of development of health
technology assessment (HTA) (Table 1). Expenditure data shown
in Table 1 for 2008 were converted at purchasing power parity to
US dollars.
In 2008, government expenditure on health per capita in
Australia was approximately 60 times that of China and 20
times that of Thailand. The percentage of gross domestic prod-
uct spent on health care in Australia is twice that of China and
Thailand, and the percentage of government-funded health
care of total health care is considerably low for China. The pro-
portion of private expenditure on pharmaceuticals in both
China and Australia is similar and reflects those of established
market economies; in Asia, almost half of all pharmaceutical
expenditure is privately funded. Each of the three countries has
its own unique challenges and opportunities. These issues are
presented for each country following an overview of the policy
and drug listing of the three countries.
National Drug Policy and Drug Reimbursement
Policy
All three countries have the national drug policy (NDP) with three
main objectives, access, quality, and rational use (Table 2). The
Universal Health Coverage (UHC) Program is the key feature of
health insurance of all the three countries. It includes drug benefit
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Thailand
Thai NDP was first introduced in 1981. In the same year, the first
National List of Essential Drugs (NLED) was published. The Minis-
try of Public Health implemented the NLED policy by limiting the
use of government budget for purchasing only NLED drugs. In
1986, the use of the NLED was expanded to cover all public hospi-
tals through the Prime Minister Office regulation of drug procure-
ment.
Because of economic crisis in 1998, the NLED was changed
from a list of fundamental drugs to a list of drugs for all levels of
care in 1999 and used for the first time as the reimbursement list
for the Civil Servants Medical Benefits Scheme (CSMBS). After
UHC in 2001, the drug benefit packages of the three tax-based
insurance systems—the CSMBS, the Social Security Scheme,
and the Universal Coverage scheme—were based on at least the
drugs listed in the NLED and in principle can be reimbursed
without any co-payment. For the fee-for-service outpatient sys-
tem of the CSMBS, any drug not in the NLED is generally allowed
to be reimbursed. For the Social Security Scheme, the Universal
Coverage scheme, and the inpatient system of the CSMBS, drugs
are included in the capitation budget, and so health facilities
determine on their own whether they need to use other drugs
outside the NLED.
China
The Chinese health system reform is aimed at providing universal
drug coverage for all citizens by 2020. China has three basic public
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medical safety net and private medical insurance exist.
In April 2009, the Central Committee of Chinese Communist
Party and State Council issued a guideline on the medical and
pharmaceutical system reform, and the implementation plan of
the health-care reform for 2009–2011. The key reform tasks are
1) accelerate the establishment of basic health insurance sys-
tems, 2) preliminarily establish a national essential drug (ED)
system, 3) optimize the service system for primary health care,
4) steadily expand access to basic public health services, and 5)
further advance public hospital reform.
The aim of the establishment of a drug provision security system
is to ensure the safety and provision of adequate amount of EDs. The
main contents of the ED policy framework include formulating the
selectionandadjustmentof theEDs list, ensuring theproductionand
distribution of EDs, quality standards on market and reasonable
price setting, conducting a zero mark-up policy on sale, promoting
rational use and reimbursement, and monitoring and evaluation of
whole national EDs system.
The objective of establishing the national EDs system is of
great significance. It will emphasize the rational use of EDs and
Table 1 – Key health expenditure indicators for the three c
Indicator
Population (’000s)
GDP (millions, 2008 US dollars)
GDP per capita (2008 US dollars)
Total expenditure on health per capita (2008 US dollars)
Total expenditure on health as % of GDP
Government expenditure on health per capita (2008 US dollars)
Government expenditure on health (% of total health expenditure)
Total drug expenditure (millions, 2008 US dollars)
Private expenditure on drugs (%)
GDP, gross domestic product; NA, not available.
*Average exchange rate 1 US$  6.95 Renminbi (RMB, ¥)  33 baht (20
† Pharmaceuticals value sold from retail pharmacies as a proxy indic
of pharmaceuticals in hospitals.
Table 2 – National drug policy of Thailand, China, and Aus
Objectives Thailand
Access Universal access to EDs in an equitable,
inclusive, and timely manner that is
appropriate to the people’s ability to
pay and national economic
conditions.
By
Quality Development of a control system to
ensure the quality, efficacy, and
safety of drugs.
Fu
Rational use Promoting the rational use of drugs by
doctors, health professionals, and
the public.
Es
Others Development of the domestic drug
industry, biological products, and
medicinal herbs for self-reliance.
ReED, essential drug.release the economic burden of patients. To some extent, it will
also promote the integration of pharmaceutical manufacturers
and distributors in China.
In August 2009, China formally started the initiative of the
national EDs system. Several policy documents were issued,
such as “the opinion of establishing national EDs system,” “the
administrative method of national EDs,” “national EDs formu-
lary,” “a regulation of strengthening quality control and super-
vision of EDs,” and “the guidelines of clinical application of
EDs.” All EDs are reimbursed and listed on the drug reimburse-
ment list of urban and rural medical insurance schemes. The
reimbursement ratio of EDs is higher than that of non-EDs.
Australia
Australia has a well-developed process for the appraisal and list-
ing of drugs. During the 1980s, Australia embraced the use of evi-
dence-based medicine and in 1992 Australia became the first
country to require a formal assessment of the costs as well as the
expected benefits of drugs before listing on the Pharmaceutical
Benefits Schedule (PBS). Drugs listed on the PBS are subsidized by
ries.
Thailand [1] China [2,3] Australia [4]
67,386 1,328,020 21,432
275,015 4,518,638.8 847,734
4,137 3402.54 39,555
173 157.48 3,365
4.0 4.83 8.5
128 38.95 2,359
74.0 24.73 70.1
479.21 89,243 8,253 [5]
NA 24.40† 23.0 [6]
US$1.05 (2008).
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the PBS may be publicly funded through statewide formularies
and/or hospitals.
In 2000, the National Medicines Policy (NMP) was introduced.
This NMP is important because it sets the framework for oper-
ating drug policies in all states and nationally in Australia. A key
feature of this policy was the shift from inputs into health-
care programs to an emphasis on the health outcomes and
health benefits from those programs. As such, the NMP focuses
on the four central principles of universal access; standards for
quality, safety, and efficacy; “quality use of medicines”; and
maintaining the pharmaceutical industry in Australia (see
Table 2).
The PBS is part of the NMP and provides timely, reliable, and
affordable access to necessary medicines for Australians. The
PBS lists all the medicines available to be dispensed to patients
at a government-subsidized price. Most of the listed medicines
are dispensed by pharmacists and used by patients at home.
The co-payments for medicines are revised annually and cur-
rently set at a maximum of AUS$34.20 per item, and AUS$5.60
per item for concession-card holders.
National Drug List and Local Drug Formulary
The national drug lists of the three countries have different char-
acteristics depending on the situation and resources of each coun-
Table 3 – Characteristics of national health insurance and
Australia.
Characteristics Thailand
UHC The UHC began in 2001 with the
three government- subsidized
insurance systems, i.e., the
CSMBS, the SSS, and the UC
scheme.
Th
Population coverage 99.4% of Thai population in
2010.
92
Source of finance CSMBS, UC scheme: General tax
SSS: tripartite from employer
and employee
UE
UR
Drug benefit packages At least the drugs listed on the
NLED are reimbursed without
co-payment.
Al
Payment CSMBS: The OP is fee-for-
service, IP is DRGs.
OP
SSS: capitation. UC: OP is
capitation, IP is DRGs.
CSMBS, Civil Servants Medical Benefits Scheme; ED, essential drug; I
NLED, National List of Essential Drugs; OP, outpatient; RCMS, Rural
Universal Coverage; UEMI, Urban Employee Basic Medical Insuranc
Insurance.try as described below.Thailand
National list of essential drugs. The NLED has been a crucial part
of Thai NDP. It has been regularly updated and used as a tool for
promoting the rational use of drugs, drug procurement of public
hospitals, and drug reimbursement. It covers a list of drugs essen-
tial for solving the health problems of Thai people at all levels of
care. The NLED also includes herbal drugs and hospital formulary
to promote national self-reliance.
Drug selection criteria include health need, safety, efficacy,
compliance, quality, total treatment cost, cost-effectiveness,
equity, and national affordability. The NLED has five sublists to
encourage the rational drug use, which should step from stan-
dard drugs to specialized and high-cost drugs. As the insurance
system should spend more on catastrophic illnesses, the “Jor 2”
sublist was first introduced in 2008 to promote rational access to
very high cost drugs for specific population through a drug use
authorization system. In addition to the capitation budget of the
Universal Coverage scheme, hospitals can reimburse “Jor 2”
drugs.
The selection process has been carefully designed to be the
evidence-based selection system that is explicit, transparent,
explicable, and free from influence. Ethical criteria are imple-
mented through the whole process, including the process to
select a drug or the recruitment of committee members. Mem-
bers with high integrity, capacity, and manageable conflict of
interest are highly important to ensure the quality of the selec-
tion process. They carefully select drugs for the NLED in a sys-
reimbursement system in Thailand, China, and
China Australia
C with three basic medical
ance systems, i.e., the UEMI,
RMI, and the RCMS.
Medicare Australia is the
government’s program to
provide UHC. It began in 1975
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provide universal health
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UHC.
Chinese population at the
f 2010.
100% (all citizens and
permanent residents).
remium contributed by
oyer (6% payroll tax) and
oyee (2% payroll tax).
Income tax surcharge (known
as Medicare levy);
exemptions for low-income
earners and surcharges for
high-income earners who do
not have private insurance
for hospital cover.
nd RCMS: contribution from
ral tax and individual
ium.
(class A) are fully
bursed; however, for nearly
non-EDs (class B), patients
to co-pay 10%–15% of the
l price.
All drugs listed on the PBS; co-
payment of up to AUS$34.20
for PBS-listed medicines or
AUS$5.60 for concession-card
holders.
IP service payment is based
e-for-service, flat rate, case
ent, and global budget
ol.
Public hospital IP and OP care is
free, fee-for-service for
private hospital care; primary
care is funded on a fee-for-
service basis through
Medicare Australia with co-
payments to GPs.
atient;.
ent Cooperative Medical System; SSS, Social Security Scheme; UC,
C, Universal Health Coverage; URMI, Urban Resident Basic Medicaldrug
e UH
insur
the U
% of
end o
MI: p
empl
empl
MI a
gene
prem
l EDs
reim
2000
have
retai
and
on fe
paym
contr
P, inp
Resid
e; UHtematic way with predefined criteria.
N
(
c
c
N
f
G
(
t
o
q
N
t
q
m
b
m
N
s
r
i
t
a
d
c
s
E
a
i
p
G
a
n
m
t
l
r
o
o
j
i
v
t
E
p
i
z
a
i
a
t
t
t
t
p
e
t
i
q
m
t
f
t
m
p
d
a
c
f
s
a
w
e
g
i
c
S129V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 2 6 – S 1 3 1Listed drugs on theNLED. Three levels ofmechanisms govern the
LED selection. The first level consists of 18National Expert Panels
NEPs) for NLED selection in different therapeutic drug classes in-
luding herbal drugs. The second one is theWorking Group for the
oordination and consolidation of NLED. The Subcommittee on
LED makes the final decision based on the recommendation
rom both two levels. In addition, the Health Economics Working
roup and the PriceNegotiation forNLED selectionWorkingGroup
PWG) support relevant economic data.
The NEPs consider all drugs proposed by anyone. To facilitate
he explicit evidence-based selection process, the scoring system
f Information, Efficacy, Safety, Administration restriction, Fre-
uency of drug administration (ISafE) scoring system and the
LED adjusted cost index (EMCI) has been developed as a selection
ool [7]. In case of the ISafE system being nonapplicable or inade-
uate for decision making, an independent review of drug infor-
ation is required. The NEPs focus more on technical evidence
ecause most members are qualified physicians, dentists, phar-
acists, and experts from universities and hospitals.
The Working Group for the coordination and consolidation of
LED coordinates and consolidates the proposedNLEDwith empha-
is on conflicting results fromdifferentNEPs andhigh-concerndrugs
egarding cost-effectiveness, ethics, equity, and national affordabil-
ty.
In case of important drugswith very high cost, the Subcommit-
ee will request for local cost effectiveness analysis studies as well
s total budget implications. If the local studies do not exist, the
rugs will be prioritized by the Subcommittee by using predefined
riteria such as burden of diseases and life-saving drugs. The local
tudies of the top 15 priority drugs will be conducted by the Health
conomics Working Group or nonprofit research organizations as
ppropriate, while the rest will be conducted by agencies propos-
ng such drugs including drug companies. All studies have to com-
ly with the Thai HTA guidelines. The Health Economics Working
roup will assess the study and make its recommendation. In
ddition, the PWG will concurrently negotiate the drug price as
ecessary to support NLED decision making.
The final decision lies with the National Drug System Develop-
ent Committee. The committee, however, has delegated the au-
hority to the Subcommittee on NLED. The Subcommittee regu-
arly meets once a month to make a final decision based on the
ecommendations from the two levels. The official announcement
f the NLEDwill be published in the royal gazette as well as posted
n the Web site of Thai Food and Drug Administration.
China
National essential medicines list. The number of drugs listed on
the essential medicines list (EML) has been changing since 1982.
The highest number of drugs was in the 1994 version, which con-
tained 699 Western drugs and 1699 Chinese traditional drugs.
A new EML for grassroots health facilities was issued by the
Ministry of Health in 2009. The list is composed of 307 EDs—205
Western and 102 traditional drugs—and all raw materials of Chi-
nese drugs and herbs. The selection criteria include necessity for
prevention and treatment, safety and efficacy, reasonable price,
and sufficient supply. Starting from 2009, all government-run ur-
ban community health centers and rural township health centers
have to store and use EDs. By the end of 2010, 57.2% of govern-
ment-run primary health institutions, including 14,000 urban
community health centers and 23,000 rural township health cen-
ters, in China had established the ED system. The national ED
system had complete coverage in 2011. By 2020, China will have a
fully comprehensive national ED system.
The bulk purchasing of EDs has been accomplished. A procure-
ment leadership group has been organized in each province. Gov-
ernment-led bidding platforms through online purchasing of EDs rhave been implemented in all 31 provinces. Those purchasing
bodies are nonprofit organization to ensure the supply of EDs. The
average price of EDs in different provinces has declined by 25%
(10.3%–53.2%).
The economic burden of population has been released signifi-
cantly. On the one hand, the number of ambulatory visits and
admissions to the hospitals have increased in all regions having
the ED system; on the other hand, the average cost per clinical visit
and drug cost per prescription have declined. Another important
EDs policy is zero mark-up; it refers to a policy of no additional
margin when a health institution sells drugs. The transaction
costs will be subsidized by the government. All EDs can be reim-
bursed from the three medical insurance systems. For instance,
the Urban Basic EmployeeMedical Insurance drug reimbursement
list contained 2151 items, that is, 1164 Western chemical drugs
and 987 Chinese traditional drugs. All 307 EDs belong to class A
and will get full reimbursement. Each province will modify its
medical insurance drug reimbursement list accordingly, which in-
cludes all additional items in the provincial supplementary EML.
Listed drugs on the national EML. The national EML will be ad-
usted dynamically. The number of items, classification, and mix
n EML will be increased continuously. In principle, it will be re-
ised every 3 years; if necessary, the Working Committee of Na-
ional Essential Medicine will adjust it accordingly.
The HTA has not been widely used in the EML selection. The
ML selection is mainly based on clinical opinion leaders’ best
ractice. Several rounds of expert meetings will be held before
ssuing the national EML. The present national EML lacks authori-
ation; it will be revised soon in 2012.
Australia
Pharmaceutical benefits schedule. The PBS began in June 1948 as
n “EDs list” for pensioners, and it has subsequently developed
nto a much larger scheme. The objective of the PBS now is to give
ll Australian residents access to prescription medicine in a way
hat is affordable, reliable, and timely [8]. The focus is on main-
aining the health of the community in away that is cost-effective;
hus, the PBS is most applicable to pharmaceuticals supplied
hrough community pharmacies and outpatient pharmacies at
ublic hospitals.
Listing drugs on the PBS. Any product (imported, manufactured,
xported, or modified) must be “sponsored” by an Australian en-
ity. Application to the Therapeutics Goods Administration (TGA)
s made by the sponsor; the TGA assesses the safety, efficacy, and
uality of the drug. This includes factors ranging from an assess-
ent of the ingredients, potential for harm from long-term use,
he therapeutic claims, to labeling. Before 2011, a draft decision
rom the TGA’s delegate was required prior to the sponsor submit-
ing an application to the Pharmaceutical Benefits Advisory Com-
ittee (PBAC) for government subsidy (since January 2011, the
rocess can be undertaken concurrently). The PBAC is an indepen-
ent statutory committee that meets three times a year to assess
pplications for listing on the PBS based on the clinical benefit and
ost-effectiveness compared with other treatments or products
or the same condition or use [9]. The PBAC is supported by two
ubcommittees—the economics subcommittee, which evaluates
ll major submissions, and the drug utilization subcommittee,
hich advises on likely uptake and monitor the use of drugs. The
conomics subcommittee is supported by five contract evaluation
roups who, for each submission from a sponsor, undertake an
n-depth evaluation of the indication and listing requested, clini-
al evidence, cost-effectiveness, and financial impact.
The PBACmay reject an application ormake recommendations
egarding a medicine’s uses and any conditions or restrictions on
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subsidy of a medicine in line with only that independent recom-
mendation [9]. The Pharmaceutical Benefits Pricing Authority is a
nonstatutory committee that meets three times a year following
PBACmeetings. It may recommend either a ceiling price or a price
range for an item that has been approved by the PBAC following
negotiation.
How well is the PBS working? The PBAC provides an efficient
HTA process for the subsidy of medications that relies on evi-
dence-based medicine. Each year more than 100 submissions for
subsidy of drugs are appraised by the PBAC. For example, the PBAC
considered 61 major and 94 minor submissions in three meetings
(July 2010, November 2010, and March 2011). Submissions to list
new medicines on the PBS or to make substantial changes to cur-
rent listings are generally classified as major submissions and
those that relate to new forms of previously listed products and
changes to the conditions of use, for example, change in maxi-
mum quantity/repeats or clarifying the wording of a restriction
(while not altering the intended use), are considered to be minor
submissions. Major submissions require presentation of an eco-
nomic evaluation,whereasminor submissions usually do not. The
PBAC now includes appraisal of vaccines in its remit. Since 2010,
the cost to submit a dossier has been recovered from the sponsor
in the formof a fee at lodgment of a submission; these dossiers can
be voluminous (often in excess of 1000 pages), and the commen-
taries from the evaluation groups are usually 70 to 120 pages in
length. In 2010, thereweremore than 600 different substances and
3000 products listed on the PBS; the vast majority of these had
undergone the rigorous HTA process described above.
This process has resulted in lower cost for new/unique sub-
stances compared with that in other countries (e.g., the prices of
new substances in Australia are approximately 50% lower than in
the United States). The prices for generic and “me-too” drugs,
however, are relatively higher. For example, a 40-mg tablet of sim-
vastatin is AUS$1.00 compared with an equivalent cost of
AUS$0.11 in the United Kingdom and AUS$0.05 in New Zealand
[10]. This pricing structure is partly due to the use of value-based
pricing, which operates in Australia. That is, any additional cost
for the use of a drug should be reflected in the value of any ex-
pected additional health gains in society using the cost per quali-
ty-adjusted life-years framework where appropriate.
Local Drug Formulary
Thailand
Public hospitals develop their own hospital drug lists based on the
NLED. In addition, the government issued the 1992 Prime Minister
Office regulation for drug procurement. The regulation stipulates
that all public hospitals use 80% and 60% of the government bud-
get, respectively, to buy drugs listed in the NLED. Drugs are pur-
chased by their generic names at the price capped by the Median
Drug Price System. Therefore, hospitals can have both the drugs
listed and not listed in the NLED. Because the regulation covers
only government budget, large public hospitals purchase more
non-NLEDs by using other sources of finance.
China
Considering the variation of local socioeconomic condition and
the reality of drug utilization in different provinces, at the begin-
ning stage of the national EDs system, the local government is
allowed to adjust the national EML and select some non-national
EML as provincial supplementary EML. The number of items and
strengths selected is based on the characteristics of clinical use,
requirements in medical settings, and reference of international
experiences. Many provinces have increased the number of drugsin their local supplementary lists, which vary from an additional
64 to 381 items because of no critical criteria for drug selection.
Nevertheless, all supplementary EMLs should be implementedun-
der the same policies, for example, bulk purchasing and zero
mark-up policy on sale.
Australia
Australian hospitals generally have their own formularies; the ex-
ceptions are Queensland and Western Australia where state for-
mularies are used. In those states, hospitals may also have their
own formularies to list drugs for specific use including treatment
of extraordinary cases. Hospitals tend to operate formulary-listing
policies based on recommendations of committees mostly com-
posed of clinicians. This has led to some inequities where patients
are able to access different medicines depending on which hospi-
tal they attend.
Discussion
Thailand
The NLED has been referred by the regulation related to drug pro-
curement and used as the drug benefit package for national health
insurance systems. As a result, it is the right of Thai people to
access and reimburse drugs listed in the NLED. There are, how-
ever, still some important challenges, that is, irrational use of
drugs not on the NLED, pressure from the industry, and conflict of
interest among the selection members. Moreover, the unafford-
able drug price is now increasing. To cope with these problems,
the selection process should be carefully designed to be the evi-
dence-based selection system that is explicit, transparent, expli-
cable, and free from commercial influence. We need more capac-
ity to assess very high cost drugs. Various measures other than
drug selection are also crucial. We learned that price negotiation,
acceleration of the local production of NLED, and the implemen-
tation of Trade Related Aspects of Intellectual Property Rights flex-
ibilities can solve some problems and should be appropriately ap-
plied to suit appropriately in certain situations.
China
After a 3-year implementation, very good progress has beenmade
in establishing the ED system. The number of drugs in the national
EML, however, is not enough to meet the needs of treatment in
chronic diseases. Another issue is that there is no long-term poli-
cies by which government subsidizes the loss of zero mark-up in
grassroots health facilities. Usually, the price difference between
wholesale and retail of pharmaceuticals is part of hospital reve-
nue. If getting rid of drugmark-up, hospitals require government’s
financial support to maintain the operational cost and provide
remuneration of medical staff.
Lack of qualified medical staff in the glassroots medical facili-
ties also has an influence on service capacity in urban community
health centers and rural township health centers. The quantity
and quality of medical professionals need to be improved in the
future.
Australia
There are system-wide and technical opportunities and chal-
lenges for drug listing in Australia. To improve health system per-
formance, change at the system level is required. Since 2011, the
TGA and PBAC processes are to run concurrently. This is expected
to reduce the total time to access new drugs. In addition, the gov-
ernment is introducing a “Managed Entry scheme”; this is amech-
anismwhereby the PBACmay recommend PBS coverage at a price
justified by the existing evidence, pending submission of more
S131V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 2 6 – S 1 3 1conclusive evidence on the cost-effectiveness to support listing
and the price of the drug. The PBAC will provide advice in relation
to sources of uncertainty and specific evidence required to support
a subsequent application [11]. Thus, this is amove toward efficient
coverage with evidence development with agreements around
risk sharing.
The development of the HTAwith cost-effectiveness analyses at
state and hospital levels to provide informed decision making is an
area that requires substantial development. Thiswill require amajor
funding commitment by governments to train the workforce with
skills to undertake and interpret HTAs, including full economic eval-
uations. Committees that do not adequately assess the evidence on
safety, effectiveness, and cost-effectiveness may face the conse-
quences from poor decisions, especially in the current climate of
fiscal constraint.
Conclusions
TheNDP of all the three countries serves as a common framework to
promote equity and sustainability of theUHC. The selection of EDs is
one of the core principles of theseNDPs. All the three countries care-
fully select drugs on thenational drug lists (NDL) anduse theNDLsas
their reimbursement list to ensure higher quality of care and better
value for money. The three countries are in different situations on
the UHC and face different challenges on the development of their
NDL system.
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